Nomura Holdings Inc Exelixis, Inc. Transaction History

Nomura Holdings Inc

$41.1 Billion
Q3 2024

A detailed history of Nomura Holdings Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Nomura Holdings Inc holds 26,708 shares of EXEL stock, worth $972,972. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,708

Previous 26,708 -0.0%

Holding current value

$972,972

Previous $693,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $586,507 - $737,140	26,708 New	26,708 $693,000
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $981,633 - $1.16 Million	48,668 New	48,668 $1.15 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $2.63 Million - $3.3 Million	136,668 Added 234.42%	194,968 $4.68 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $1.11 Million - $1.33 Million	58,300 New	58,300 $1.27 Million
Q2 2021 Aug 16, 2021	SELL	$17.95 - $25.56 $682,100 - $971,280	-38,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $236,095 - $290,030	-11,500 Reduced 23.23%	38,000 $858,000
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $300,560 - $385,050	17,000 Added 52.31%	49,500 $880,000
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $615,225 - $804,375	32,500 New	32,500 $698,000
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $258,262 - $312,391	-13,915 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$22.15 - $31.89 $308,217 - $443,749	13,915 New	13,915 $308,000
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $895,128 - $1.14 Million	-36,943 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $862,619 - $1.08 Million	36,943	36,943 $894,000

Others Institutions Holding EXEL

# of Institutions

508

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

News

Stay updated on Nomura Holdings Inc with notifications on news.

Account

Nomura Holdings Inc Exelixis, Inc. Transaction History